MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data
06Dec

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

December 6, 2021 Metabolon Biomarkers, Drug Development 77
Previous studies have shown that elevated bile acid concentrations are associated with the presence and severity of liver disorders. Given the link between bile acids and metabolic regulation, there is growing interest in understanding how bile acid dysregulation may contribute to NASH pathogenesis and progression.
Read more
01Sep

Metabolomics Drives Identification of Rare Disease Signatures and Diagnoses

September 1, 2021 Metabolon Biomarkers, Capabilities, Drug Development, Precision Medicine 74
Rare diseases represent a unique challenge in clinical medicine. These diseases signify that few people have these diseases and even fewer have a successful diagnosis. Rare diseases are classified in many categories, including metabolic diseases, rare cancers, autoimmune diseases, blood disorders, digestive diseases, endocrine system disorders, nervous system diseases, reproductive disorders, and musculoskeletal diseases.
Read more
03Aug

Uncovering the metabolic basis for population differences in the immune response to malaria.

August 3, 2021 Metabolon Biomarkers, Blog, Omics 107
Malaria is a global health epidemic, with an estimated 229 million cases per year resulting in over 400, 000 deaths with the majority of these deaths being in children under the age of 5. The vast majority of cases in sub-Saharan Africa are caused by the Plasmodium falciparum parasite and transmitted via mosquitos. There is currently no approved vaccine for malaria and antimalarial drug resistance is a growing concern. There is hope that a better understanding of the interactions of the parasite and host metabolism could yield better treatment options.
Read more
21Jul

New Hope for Rare Disease Treatments

July 21, 2021 Metabolon Biomarkers, Drug Development, Precision Medicine 96
The number of rare diseases identified increases with each passing year due to the advent of deeper genome sequencing for patients, characterization of metabolic pathways, and identification/stratification of patients that historically were thought to have other diseases. Metabolomics is uniquely situated to identify biomarkers of disease for numerous rare diseases because it can identify the small molecule profiles of individual patients and link the changes to specific genetic mutations.
Read more
28Apr

Metabolomics and Shotgun Metagenomics Reveal Evidence That Glyphosate Exposure Affects the Gut Microbiome

April 28, 2021 Metabolon Biomarkers, Capabilities, Microbiome 97
A multi-omics approach provides valuable insights for investigating complex areas of science to enhance our understanding while Metabolon’s platform delivers interpretive depth not possible elsewhere. Additionally, the profiling of multiple matrices allowed for analysis of both microbiome derived compounds as well as how those changes may be reflected systemically, giving the work a much broader impact.
Read more
01Apr

Specific Metabolic Pathways Underlie Noncommunicable Disease Multimorbidity

April 1, 2021 Metabolon Biomarkers, Drug Development, Population Health, Precision Medicine 91
Metabolomics helps understand shared etiologies of comorbidities, which could result in better treatments for patients. A detailed analysis of the human metabolome in so many individuals offered a comprehensive readout of human physiology that enabled to characterize pathways associated with and across 27 incident noncommunicable diseases.
Read more
15Mar

Can Sebum be Used as a Diagnostic Biofluid for Parkinson’s Disease?

March 15, 2021 Metabolon Biomarkers, Drug Development, Microbiome 100
Metabolomics offers unique hope in the battle against Parkinson’s disease through a simple skin swab. A recent study published in Nature Communications reports that sebum obtained from a simple skin swab can be used to help diagnose people with Parkinson’s based on the patient’s pattern of skin lipids and related-metabolites.
Read more
16Feb

Metabolomics to Investigate the Immuno-metabolism and Inflamm-aging Triggered by Viral Infections

February 16, 2021 MetabolonDesign Biomarkers, Omics 133
As HIV, the virus that causes AIDS, continues to be a major global health challenge, researchers like Dr. Ujjwal Neogi, Karolinska Institute, play a vital role in unraveling the mechanisms of HIV pathogenesis and natural control mechanism that can aid for functional cure or vaccine developments.
Read more
12May

New Hope for Patients with Inborn Errors of Metabolism and Rare Diseases

May 12, 2020 Metabolon Biomarkers, Capabilities, Precision Medicine 142
Sometimes, there is no playbook. That’s often the case with inborn errors of metabolism (IEM), defined as rare genetic disorders that cause alterations or deficiencies in enzymes involved in metabolism, and other rare diseases. A patient may exhibit clinical signs that don’t map to specific disorders, or a screening panel may come back with no clues. In these frustrating situations, clinical researchers – and patients – need more places to turn for answers.
Read more
28Apr

Delivering Clinical Insights with Targeted Biomarker Assays

April 28, 2020 Metabolon Biomarkers, Capabilities, Drug Development, Precision Medicine 143

Metabolomics reveals biological insights otherwise unseen, making it a crucial component of drug development. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of technology and expertise is required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.

Metabolomics reveals biological insights otherwise unseen, making it a crucial component of drug development. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of technology and expertise is required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.

At Metabolon, we understand the crucial role targeted small molecule assays play in drug development, and we’ve established best-in-class expertise. Metabolon has developed quantitative assays for more than 900 biochemicals in over 20 different matrices, including more than 150 qualified and/or validated targeted biochemical assays for pharmaceutical and biotechnology research and development. These assays focus on specific metabolites or metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research.

Our approach speaks directly to the questions biopharma research directors are seeking to answer, such as understanding their therapeutic’s mechanism of action, establishing pharmacodynamics, gauging safety and efficacy, defining patient segmentation, and conducting post-market surveillance. Once the critical biomarkers that are most important to researchers are identified through discovery, a more precise and accurate quantitation of the biomarkers is sought. Metabolon’s strategic services offer biopharma clients global discovery followed with a direct targeted approach to dig deeper into promising and relvant biomarkers.

Metabolon’s targeted assay program is uniquely situated to fit into this workflow.

Targeted biomarker assay development is a natural progression following discovery using Metabolon’s first-in-class metabolomics platform. Metabolon’s discovery platform uses statistical approaches to assess the relative quantity of thousands of biomarkers. Our targeted assay program picks up from there, taking the discovery work and developing a more precise, accurate measurement of those few molecules that are of most interest. We apply LC-MS/MS based methods to determine absolute quantities of important biomarkers, using labeled internal standards as well as calibrators.

Our expertise in the measurement of endogenous biomarkers is unique and second to none. Most bioanalytical services offer expertise in exogenous biomarker measurements, such as the drug of interest or compounds that are exogenously introduced into a system. Metabolon targeted assays measure endogenous biomarkers naturally found at various levels within biological systems. Since endogenous biomarkers are sometimes present at the lower limits of analytical detection, the sensitivity of the assay becomes paramount. Furthermore, modest changes in biomarker levels may have biological relevance; Metabolon’s highly accurate targeted assays are required to tease out even modest changes in analyte levels. Our team of Ph.D. level method development scientists have a degree of experience in endogenous biomarker assay development that few places, if any, in the world can match. Our scientists are highly efficient and experienced in endogenous small molecule analysis, bringing additional data and actionable insights to drug development and clinical trials. No other bioanalytical company can translate metabolomic data and biomarker discovery into valuable biological insight using targeted LC-MS/MS analysis in the way that we can.

Finally, Metabolon’s capability is unique because we can operate under a research or clinical setting. In addition to our targeted work meeting specific client study demands, we also develop assays specifically used in clinical testing. Some of the pre-developed targeted assays offered by Metabolon include:

  • Fatty acid metabolism panel
  • Short-chain fatty acid panel
  • Bile acid panel
  • Cholesterol metabolism panel
  • Stratum corneum panel
  • Sebum lipid panel
  • accuGFR™ panel (to estimate glomerular filtration rate)
  • 7 alpha-hydroxy-4-cholesten-3-one (C4) panel
  • Metal ion panel

LC-MS/MS-based assays can be customized based on client needs and developed under the quality system for research use only (RUO) or validated under Good Clinical Practice (GCP) and Clinical Laboratory Improvement Amendments (CLIA). Metabolon is ISO 9001: 2015 certified for analytical and diagnostic testing of biological specimens and accredited by the College of American Pathologists for diagnostic testing on human specimens.

Nowhere else will you find a laboratory like Metabolon’s that combines a world-class metabolomics discovery platform with a highly sophisticated analytical chemistry laboratory doing targeted analysis the way we do it. We have spent nearly 20 years building the best metabolomics competency in world to enable, accelerate and support drug development through biomarker discovery, understanding mechanism of action, patient stratification and more.

We proudly cover the whole breadth of the biopharma pipeline, from discovery to targeted analysis to clinical trial support, because your success is our goal.

Is your study yielding all the insights it could be? Download our free infographic to learn more about the five risks of drug development and how you can avoid them with metabolomics, and contact us today at [email protected] to get started.Request a quote for our services and get more information on sample types and handling procedures.JTNDZm9ybSUyMGlkJTNEJTIybWt0b0Zvcm1fMTAwMyUyMiUzRSUzQyUyRmZvcm0lM0UlMEElM0NzY3JpcHQlM0UlMEFNa3RvRm9ybXMyLmxvYWRGb3JtJTI4JTIyJTJGJTJGaW5zaWdodHMubWV0YWJvbG9uLmNvbSUyMiUyQyUyMCUyMjMwMS1EQUQtNzQyJTIyJTJDJTIwMTAwMyUyOSUzQiUwQSUzQyUyRnNjcmlwdCUzRQ==

Read more
    12

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in